26.07.2019 • News

Michael Quirmbach Appointed as CEO and President of CordenPharma

CordenPharma has appointed Michael Quirmbach as its new CEO and president....
CordenPharma has appointed Michael Quirmbach as its new CEO and president. Source: CordenPharma

CordenPharma has appointed Michael Quirmbach as its new CEO and president, effective Aug. 1, 2019. He is going to succeed Riku Rautsola who will transition to the role of a senior advisor to the executive leadership team.

Quirmbach joined CordenPharma in October 2014 as chief business officer and has been a member of the executive leadership team. Prior to joining CordenPharma, he held several management positions at Siegfried, Dr. Reddy’s and Solvias. Quirmbach holds a degree in chemistry and a PhD from the Max Planck Research Group at the Institute for Organic Catalysis Research in Rostock, Germany, as well as an MBA from La Salle University in Philadelphia, USA.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Top-Feature

most read

Photo
News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.